J&A Procurement of Smallpox (Mpox) Vaccine for the Strategic National Stockpile
ID: HHSO100201700019CType: Justification
AwardedSep 27, 2017
Award #:HHSO100201700019C
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFOFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSEBARDA - ASPR / DAAPPO / BARDA DCMAWASHINGTON, DC, 20515, USA

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/3272500464df4074bcf512146f1f5fec/view
Timeline
    Description

    The Department of Health and Human Services, specifically the Office of Assistant Secretary for Preparedness and Response (BARDA), is seeking to procure additional doses of the JYNNEOS™ vaccine for the Strategic National Stockpile in response to the ongoing monkeypox outbreak. The procurement aims to rapidly secure 11 million doses of the vaccine by utilizing existing bulk drug substance and to enhance manufacturing capacity through technology transfer to contract manufacturing organizations. The JYNNEOS™ vaccine is critical as it is the only licensed vaccine for both smallpox and monkeypox, making it essential for public health preparedness. Interested parties can contact Yifan Yang at yifan.yang@hhs.gov, with the total estimated value of the contract modification being $992,400,000.

    Point(s) of Contact
    Yifan Yang
    yifan.yang@hhs.gov
    Files
    Title
    Posted
    JA MPox.pdf
    Similar Opportunities
    Japanese Encephalitis Vaccine
    Health And Human Services, Department Of
    The Department of Health and Human Services is seeking suppliers for the Japanese Encephalitis Vaccine, specifically the Ixiaro brand or an equivalent product. The procurement involves a requirement for 800 syringes of the vaccine, identified by NDC 42515-0002-01 and NSN: 6505-01-607-7018, which is critical for immunization against Japanese Encephalitis, a serious viral infection. Interested vendors should note that the place of performance is Perry Point, Maryland, and they can reach out to Tim Bouchelle at Timothy.Bouchelle@hhs.gov or by phone at 443-947-6039 for further inquiries. This opportunity is categorized under the Pharmaceutical and Medicine Manufacturing industry, with no set-aside restrictions.
    65--TYPHOID VI POLYSACC
    Dept Of Defense
    The Department of Defense, through the Defense Logistics Agency (DLA Troop Support), is seeking quotes for the procurement of Typhoid VI Polysaccharide vaccine, identified by NSN 6505013856328. The requirement includes the delivery of 5 units to the USS Emory S. Land AS 39 and 100 units to the USS McCampbell DDG 85, both due within 20 days after order. This vaccine is critical for maintaining the health and readiness of military personnel, particularly in environments where typhoid fever is a risk. Interested vendors, particularly those classified as Service-Disabled Veteran-Owned Small Businesses (SDVOSBC), must submit their quotes electronically, with further inquiries directed to the DLA at DibbsBSM@dla.mil.
    Vaccines for Children (VFC) FY26
    Health And Human Services, Department Of
    The Centers for Disease Control and Prevention (CDC) is seeking manufacturers to provide pediatric vaccines under the Vaccines for Children (VFC) program through an Indefinite Delivery Indefinite Quantity (IDIQ) contract. This procurement aims to secure a wide range of vaccines, including DTaP, Hepatitis A and B, MMR, and Pneumococcal, for eligible children aged 18 and younger, ensuring that those who are Medicaid-eligible, uninsured, or American Indian/Alaska Native receive necessary immunizations. The contract period spans from April 1, 2026, to March 31, 2027, with a maximum combined value exceeding $13 billion, and interested parties must adhere to strict requirements regarding shelf life, packaging, and delivery timelines. For further inquiries, potential offerors can contact James Sprigler at zbs6@cdc.gov or Chad Turner at ukr9@cdc.gov.
    National Clinical Vaccination (NCV) Contract Extension
    Homeland Security, Department Of
    The Department of Homeland Security, specifically the Federal Emergency Management Agency (FEMA), is extending the National Clinical Vaccination (NCV) Contract to secure contractor-managed licensed medical professionals for COVID-19 vaccine administration. This extension aims to support federal assistance to state, local, tribal, and territorial partners in response to Major Disaster Declarations related to the COVID-19 pandemic, in accordance with various legislative acts including the Robert T. Stafford Act and the Public Health Service Act. The services are critical for ensuring effective vaccine distribution and administration during ongoing public health emergencies. Interested parties can reach out to Michael Bonds at michael.bonds@fema.dhs.gov or call 202-257-8893 for further details regarding this opportunity.
    National Immunization Survey - Flu Q2-Q4 2023 Bridge Contract
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), is seeking to continue the National Immunization Survey through a bridge contract for the second to fourth quarters of 2023. This contract, awarded to the National Opinion Research Center (NORC), aims to ensure the timely collection and analysis of immunization data, which is critical for public health decision-making and policy formulation. The justification for this contract was made under the authority of FAR 6.302-2 due to unusual and compelling urgency, and the associated Justification and Approval for Other Than Full and Open Competition (JOFOC) will be available for review for 30 days following the contract award. For further inquiries, interested parties may contact Joshua Houston at pkf5@cdc.gov.
    Synthesis of Self-Amplifying Nucleic Acid Constructs
    Agriculture, Department Of
    The Department of Agriculture, specifically the Agricultural Research Service, is seeking quotations for the synthesis of five lipid nanoparticle-encapsulated self-amplifying nucleic acid constructs based on the Venezuelan equine encephalitis virus (VEEV). The objective of this procurement is to design, synthesize, produce, and encapsulate these gene constructs, which are critical for research at the US National Poultry Research Center in Athens, GA. This total small business set-aside contract, classified under NAICS code 541380, has a small business size standard of $19.0 million and will be awarded based on the lowest price technically acceptable criteria, with deliverables required within 30 days post-award. Interested parties should direct inquiries to Jessica Pacheco at jessica.pacheco@usda.gov, with quotes due electronically by January 5, 2026, and held firm for 90 days.
    Animal Vaccines
    Agriculture, Department Of
    The Department of Agriculture, specifically the Agricultural Research Service (USDA ARS), is seeking quotations for the procurement of animal vaccines under solicitation number 1232SA26Q0014. The contractor will supply essential vaccines for research animals, including beef cattle, swine, and sheep, with specific requirements for products such as Guardian, Brute Pour On, and PregGuard Gold FP10, among others, all with expiration dates of January 1, 2027, or later. This procurement is critical for maintaining the health of research animals at the Roman L. Hruska U.S. Meat Animal Research Center in Clay Center, Nebraska, with a delivery deadline set for January 5, 2026. Interested vendors must acknowledge the amendment to the solicitation, submit their quotes by January 6, 2026, and direct any inquiries to Brian Brusky at brian.brusky@usda.gov or by phone at 608-215-2837.
    GMP Manufacturing of CDC FluSC2 Multiplex EUA Kit
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), has awarded a contract for the GMP manufacturing of the CDC FluSC2 Multiplex EUA Kit to Biosearch Technologies, Inc. This contract, valued at $399,993, entails the production of 1,020 vials of oligonucleotide primers and probes, adhering to Good Manufacturing Practices (GMP) as defined under 21 CFR 820, with a required delivery date of September 25, 2023. The specific internal BHQnova quencher design of the probes is critical for the diagnostic assay, which has received Emergency Use Authorization (EUA) from the FDA, and no other suppliers have been identified that can meet these stringent requirements. For further inquiries, interested parties may contact Mark Draluck at syq1@cdc.gov or Devin Barich at uca9@cdc.gov.
    COVID 19 Tests
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Office of Assistant Secretary for Preparedness and Response, is seeking procurement for COVID-19 tests. The opportunity involves the acquisition of in vitro diagnostic substances, reagents, test kits, and sets, with a focus on ensuring compliance with the Trade Agreements Act (TAA). This procurement is critical for enhancing the nation's testing capabilities in response to the ongoing pandemic. Interested vendors can reach out to Junli Collins at junli.collins@hhs.gov or Judy Williams at judy.williams2@hhs.gov for further details, as outlined in the attached justification document.
    6505--Ustekinumab Pens/Syringes or Biosimilar
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Ustekinumab Pens/Syringes or Biosimilars, aimed at supplying various federal health entities including the Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center. The contract will be awarded for an initial period of one year, with the possibility of four additional one-year option periods, ensuring a consistent supply of these critical pharmaceutical products through the VA and DoD Pharmaceutical Prime Vendor Programs. Offerors must provide drugs with unique National Drug Code (NDC) numbers and ensure that any biosimilar products meet FDA licensing requirements, as outlined in the FDA Purple Book. The solicitation is expected to be released around January 12, 2026, with a tentative closing date of January 27, 2026; interested parties should direct inquiries to Chris Carthron at Christopher.Carthron@va.gov or (708) 786-4980.